Cormorant Asset Management, LP Chemomab Therapeutics Ltd. Transaction History

Cormorant Asset Management, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$2.33 - $4.0 $2 - $4	1 Added 0.0%	288,169 $718,000
Q1 2022 May 16, 2022	BUY	$3.53 - $7.2 $1.02 Million - $2.07 Million	288,168 New	288,168 $1.38 Million

2.68M

Ticker CMMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,431,700
Market Cap $18.2M
Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.